A preplanned unblinded interim analysis was conducted when approximately 80% of participants completed the week 24 visit or prematurely discontinued the study treatment
Our process always begins with a thorough consultation to ensure you're a suitable candidate
These medicines include semaglutide (Ozempic, Wegovy, Rybelsus), liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), and tirzepatide (Mounjaro), which is a dual GIP/GLP-1 receptor agonist rather than a pure GLP-1 agonist
Personalized Treatment Plan: Sermedspa recognizes the uniqueness of each individuals health journey
Removing the stumbling block of exosome applications in clinical and translational medicine: expand production and improve accuracy
Distribution of pigment to skin cells for visible color change